Favorable outcomes, minimal adverse effects seen in solid organ transplant recipients who received monoclonal antibody therapy for COVID-19.
Survival up to five years after a heart transplant is similar for patients aged 70 years and older and those younger than 70 years.
Adult patients anticipating liver transplantation could benefit from the selective use of three-tiered cardiac risk stratification protocol.
Young Black heart recipients have an increased risk for mortality in the first year after transplant.
Blood test measuring percent donor-derived cell-free DNA could eliminate much of the need for endomyocardial biopsy.
ACC releases recommendations regarding the use of coronary CTA as an initial tool for the diagnosis of stable coronary artery disease.
Severe obesity in organ donors is not associated with adverse heart transplant outcomes.
In the COVID-19 era, there has been a decrease in heart transplant (HT) volumes.
Thoracic organ transplantation remains a viable treatment option in patients with Eisenmenger Syndrome, although these patients are considered higher risk than other potential transplant recipients.
Lower baseline eGFR and a history of coronary artery disease may predict the risk for hemodialysis after total artificial heart implantation.